

ASX: DNA

#### **ASX RELEASE**

#### 5 February 2015

### **Notice of Exercise and Expiry of Options**

Donaco International Limited lodges the attached Appendix 3B, covering the exercise of 940,517 listed options (ASX code: DNAO) prior to their expiry date of 29 January 2015.

A total of 2,721,367 DNAO options have now been exercised since their issue date two years ago. The remaining 585,029 DNAO options have now expired unexercised.

The attached Appendix 3B also covers the recent exercise of 324,400 unlisted options by Main Ace Investment Limited. A further 238,100 unlisted options held by Main Ace expired unexercised on 17 January 2015.

Main Ace continues to hold 125,000 unlisted options expiring on 1 March 2015, and 125,000 unlisted options expiring on 17 May 2015.

#### For further information:

Ben Reichel Executive Director Phone: + 61 412 060 281

#### ABOUT DONACO INTERNATIONAL LIMITED (ASX: DNA)

Donaco International Limited operates leisure and entertainment businesses across the Asia Pacific region.

Our flagship business is the Aristo International Hotel, a successful boutique casino in northern Vietnam. Donaco operates the business and owns a 95% interest, in a joint venture with the Government of Vietnam.

Donaco is a pioneer casino operator in Vietnam. The business was established in 2002, and is located on the border with Yunnan Province, China. The property has recently been expanded to a brand new five star resort complex with 428 hotel rooms.

To learn more about Donaco visit <u>www.donacointernational.com</u>



# **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12,

04/03/13		
Name	of entity	
Don	aco International Limited	
ABN		
28 00	07 424 777	
	the entity) give ASX the following	g information.
	1 - All issues ust complete the relevant sections (attac	h sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Fully paid ordinary shares
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	A. 940,517 ordinary shares B. 324,400 ordinary shares
	be issued	
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	New ordinary shares ranking equally with existing class of quoted ordinary shares

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or	Yes
	interest payment	
5	Issue price or consideration	A. \$263,344.76
		B. \$175,176.00
6	Purpose of the issue	A. Exercise of 940,517 options (DNAO)
Ü	(If issued as consideration for the acquisition of assets, clearly identify those assets)	B. Exercise of 324,400 unlisted options by Main Ace Investment Limited
6-	T1	N
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	No
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of *securities issued without security holder approval under rule 7.1	N/A

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6d	Number of *securities issued with security holder approval under rule 7.1A	N/A	
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of *securities issued under an exception in rule 7.2	N/A	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	N/A	
-	<sup>+</sup> Issue dates	= Fohmany 2015	
7	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.	5 February 2015	
		Number	+Class
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	683,274,102	Shares (DNA)  Note: The total number of shares includes the maximum of 220,002,963 shares under the current rights issue

Number and +class of all 9 +securities not quoted on ASX (including the +securities in section 2 if applicable)

Number	+Class	
250,000	Fully vested,	
	unexpired options	
	issued to Main Ace	
	Investment Limited	
	in accordance with	
	the Subscription	
	Agreement dated 20	
	October 2011.	
4,010,511	FY14 Options issued	
	under the Company's	
	Employee Option	
	Plan, as approved by	
	shareholders at the	
	2013 AGM.	
10.027.067	EViz Options issued	
19,037,067	FY15 Options issued	
	under the Company's	
	Employee Option Plan, as approved by	
	shareholders at the	
	2013 AGM.	

10 trust, distribution policy) on the increased capital (interests)

Dividend policy (in the case of a Unchanged from that set out in the Company's prospectus dated 13 December 2012.

## Part 2 - Pro rata issue

Is security holder approval required?	N/A	
Is the issue renounceable or non-renounceable?	N/A	
Ratio in which the *securities will be offered	N/A	
<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	N/A	
<sup>+</sup> Record date to determine entitlements	N/A	
Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A	
	required?  Is the issue renounceable or non-renounceable?  Ratio in which the *securities will be offered  *Class of *securities to which the offer relates  *Record date to determine entitlements  Will holdings on different registers (or subregisters) be	

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents	N/A
	Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A

29	Date rights trading will end (if applicable)	N/A	
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?		
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A	
33	<sup>+</sup> Issue date	N/A	
	3 - Quotation of securitieed only complete this section if you are ap		
34	Type of *securities (tick one)		
(a)	✓ *Securities described in Part	1	
(b)	All other *securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities		
Entitio	es that have ticked box 34(a)		
Addit	ional securities forming a new	v class of securities	
Tick to docume	indicate you are providing the informatents	ion or	
35		securities, the names of the 20 largest holders of the the number and percentage of additional *securities	
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000		
	1,001 - 5,000 5,001 - 10,000		
+ See c	hapter 19 for defined terms.		

Appendix 3B Page 6 04/03/2013

A copy of any trust deed for the additional *securities		
es that have ticked box 34(b)		
Number of *securities for which *quotation is sought	N/A	
<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought	N/A	
Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	N/A	
<ul> <li>If the additional *securities do not rank equally, please state:</li> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>		
Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another +security, clearly identify that other +security)	N/A	
Number and *class of all *securities quoted on ASX (including the *securities in clause 38)	Number N/A	+Class N/A
	es that have ticked box 34(b)  Number of *securities for which *quotation is sought  *Class of *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment  Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another *security, clearly identify that other *security)  Number and *class of all *securities quoted on ASX (including the *securities in clause	es that have ticked box 34(b)  Number of *securities for which *quotation is sought  *Class of *securities for which quotation is sought  Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment  Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another *security, clearly identify that other *security)  Number  Number and *class of all *securities quoted on ASX (including the *securities in clause

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 5 February 2015

(Director & Company Secretary)

Print name: Benedict Reichel

== == == ==

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.